{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:45:20Z","timestamp":1758055520789,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.chest.2020.09.239","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T05:00:52Z","timestamp":1612414852000},"page":"475-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antacid Therapy in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Lee M.","family":"Fidler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri A.","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.chest.2020.09.239_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S2213-2600(17)30219-9","article-title":"Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?","volume":"5","author":"Johannson","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2020.09.239_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1378\/chest.07-1373","article-title":"Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-\u03b21 production and fibroblast proliferation","volume":"132","author":"Perng","year":"2007","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2020.09.239_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/qjmed\/hcw115","article-title":"Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity","volume":"109","author":"Ghebre","year":"2016","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.chest.2020.09.239_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.chest.2020.09.239_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2020.09.239_bib6","doi-asserted-by":"crossref","first-page":"1800376","DOI":"10.1183\/13993003.00376-2018","article-title":"The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies","volume":"51","author":"Tran","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2020.09.239_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2020.09.239_bib8","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guidelines: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2020.09.239_bib9","first-page":"165","article-title":"Management of idiopathic pulmonary fibrosis: a survey of Canadian respirologists","volume":"4","author":"Fidler","year":"2020","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"2","key":"10.1016\/j.chest.2020.09.239_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.chest.2020.08.2080","article-title":"Effectiveness of proton pump inhibitors in idiopathic pulmonary fibrosis: a population-based cohort study","volume":"159","author":"Tran","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2020.09.239_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new\u00a0user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"10.1016\/j.chest.2020.09.239_bib12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1513\/AnnalsATS.201610-764OC","article-title":"Code-based diagnostic algorithms for idiopathic pulmonary fibrosis: case validation and improvement","volume":"14","author":"Ley","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.chest.2020.09.239_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220347395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220347395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:31:06Z","timestamp":1757925066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220347395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0012369220347395"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.09.239","relation":{},"ISSN":["0012-3692"],"issn-type":[{"type":"print","value":"0012-3692"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antacid Therapy in Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.09.239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.08.2080","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}